US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Avalyn Pharma

28.49

+1.395.13%

Volume:347.62K

Turnover:9.80M

Market Cap:1.26B

PE:-12.23

High:29.00

Open:27.05

Low:26.57

Close:27.10

52wk High:40.17

52wk Low:24.15

Shares:44.33M

Float Shares:16.67M

Volume Ratio:1.31

T/O Rate:2.09%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.3300

EPS(LYR):-87.7434

ROE:-68.34%

ROA:-41.74%

PB:3.17

PE(LYR):-0.32

Loading ...

Overview Company News Filings

Avalyn Pharma Reports Phase 1 Data for Inhaled Nintedanib AP02 Showing Higher Lung Exposure, Lower Systemic Levels

Avalyn Pharma announces published results from Phase 1 trials of AP02

Avalyn Pharma Director Robert J. Meyer Files Initial Beneficial Ownership Statement

Avalyn Appoints Robert J. Meyer, Md, to Its Board of Directors

THOMSON REUTERS

Press Release: Avalyn Appoints Robert J. Meyer, MD, to Its Board of Directors

Avalyn Pharma Advances Inhaled Pirfenidone AP01 in Phase 2b MIST Trial for Progressive Pulmonary Fibrosis

One new option listing and two option delistings on August 21st

Avalyn Pharma price target raised to $57 from $53 at Morgan Stanley

Jefferies Sticks to Its Buy Rating for Avalyn Pharma Inc (AVLN)

Avalyn Pharma is Maintained at Overweight by Morgan Stanley

Avalyn Pharma Q2 EPS $(0.65) Misses $(0.53) Estimate

Benzinga Earnings

Earnings Flash (AVLN) Avalyn Pharma Posts Q2 Net Loss $28.9M, vs. FactSet Est of $28.6M Loss

MT Newswires Live

Avalyn Pharma Q2 FY26 Net Loss Widens to $28.94 Million

Press Release: Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Avalyn Pharma completes target enrollment in MIST trial

Avalyn Pharma completes enrollment in Phase 2b MIST trial of inhaled pirfenidone for progressive pulmonary fibrosis

Avalyn Pharma - Topline Data From Mist Trial Expected in Second Half of 2027

THOMSON REUTERS

Avalyn Completes Target Enrollment in Phase 2B Mist Trial of AP01 (Inhaled Pirfenidone) for Patients With Progressive Pulmonary Fibrosis

THOMSON REUTERS

Avalyn Pharma FY26 Q1 net loss widens to $26.87 million

Press Release: Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/AVLN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AVLN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVLN\",,,,,undefined,":{"symbol":"AVLN","market":"US","secType":"STK","nameCN":"Avalyn Pharma","latestPrice":28.49,"timestamp":1790798400000,"preClose":27.1,"halted":0,"volume":347615,"delay":0,"changeRate":0.05129151291512904,"floatShares":16666700,"shares":44333095,"eps":-2.33,"marketStatus":"Pre-Mkt","change":1.39,"latestTime":"10-01 05:39:37 EDT","open":27.05,"high":29,"low":26.57,"amount":9799749,"amplitude":0.089668,"askPrice":31.47,"askSize":100,"bidPrice":25.61,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.33,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790861400000},"marketStatusCode":1,"adr":0,"listingDate":1777521600000,"exchange":"NASDAQ","adjPreClose":28.49,"postHourTrading":{"tag":"盘后","latestPrice":28.49,"preClose":28.49,"latestTime":"16:10 EDT","volume":3966,"amount":112991.58,"timestamp":1790799005528,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.3125670219659196,"impliedVol":0.6739,"impliedVolPercentile":0.6786},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVLN\",,,,,undefined,":{"symbol":"AVLN","floatShares":16666700,"roa":"-41.74%","roe":"-68.34%","lyrEps":-87.743381,"volumeRatio":1.3125670219659196,"shares":44333095,"dividePrice":0,"high":29,"amplitude":0.089668,"preClose":27.1,"low":26.57,"week52Low":24.15,"pbRate":"3.17","week52High":40.17,"institutionHeld":0,"latestPrice":28.49,"eps":-2.33,"divideRate":0,"volume":347615,"delay":0,"ttmEps":-2.33,"open":27.05,"prevYearClose":18,"prevWeekClose":28.08,"prevMonthClose":28.49,"prevQuarterClose":28.49,"fiveDayClose":29.67,"twentyDayClose":35.28,"sixtyDayClose":28.42},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AVLN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"AVLN","fiscalQuarterEnding":"2026/06","expectedEps":-1.03,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"pre","actualEps":-0.98}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AVLN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AVLN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1781755200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AVLN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AVLN","date":"2026-09-29","current":-12.227468,"percent":0.970874,"low":-16.842577,"twenty":-15.410859,"median":-14.115811,"eighty":-13.252268,"high":-8.833116,"avg":-14.269184,"sd":1.291254,"marketCap":1255513250},"quantilePoints":[{"date":"2026-05-01","current":-14.471589,"twenty":-13.343894,"median":-11.652352,"eighty":-9.960811,"marketCap":1233037266},{"date":"2026-05-08","current":-13.215324,"twenty":-14.430368,"median":-13.598092,"eighty":-13.264397,"marketCap":1125998425},{"date":"2026-05-15","current":-15.026112,"twenty":-14.666899,"median":-14.368536,"eighty":-13.42143,"marketCap":1280284879},{"date":"2026-05-22","current":-13.941602,"twenty":-14.643344,"median":-13.941602,"eighty":-13.42143,"marketCap":1187880255},{"date":"2026-05-29","current":-13.931787,"twenty":-14.643344,"median":-13.931787,"eighty":-13.215324,"marketCap":1187044014},{"date":"2026-06-05","current":-13.244767,"twenty":-14.510847,"median":-13.774754,"eighty":-13.102456,"marketCap":1128507148},{"date":"2026-06-12","current":-13.774754,"twenty":-14.471589,"median":-13.774754,"eighty":-13.161343,"marketCap":1173664159},{"date":"2026-06-18","current":-14.383258,"twenty":-14.479441,"median":-13.794383,"eighty":-13.204528,"marketCap":1225511097},{"date":"2026-06-26","current":-13.585419,"twenty":-14.649233,"median":-13.936694,"eighty":-13.238878,"marketCap":1284773093},{"date":"2026-07-02","current":-14.143275,"twenty":-14.655122,"median":-14.03484,"eighty":-13.265378,"marketCap":1337529476},{"date":"2026-07-10","current":-13.557292,"twenty":-14.643344,"median":-13.937009,"eighty":-13.265378,"marketCap":1282113107},{"date":"2026-07-17","current":-12.038425,"twenty":-14.576758,"median":-13.784568,"eighty":-13.15846,"marketCap":1138473879},{"date":"2026-07-24","current":-13.937009,"twenty":-14.519455,"median":-13.774754,"eighty":-13.193732,"marketCap":1318022914},{"date":"2026-07-31","current":-13.740119,"twenty":-14.495144,"median":-13.755125,"eighty":-13.157019,"marketCap":1299403014},{"date":"2026-08-07","current":-15.329303,"twenty":-14.523759,"median":-13.762486,"eighty":-13.165961,"marketCap":1449692206},{"date":"2026-08-14","current":-15.696852,"twenty":-14.725787,"median":-13.774754,"eighty":-13.189862,"marketCap":1621704615},{"date":"2026-08-21","current":-15.932863,"twenty":-15.087944,"median":-13.934398,"eighty":-13.227101,"marketCap":1646087817},{"date":"2026-08-28","current":-15.666815,"twenty":-15.573456,"median":-13.941602,"eighty":-13.249768,"marketCap":1618601298},{"date":"2026-09-04","current":-15.207667,"twenty":-15.433025,"median":-14.088821,"eighty":-13.261019,"marketCap":1571164886},{"date":"2026-09-11","current":-14.877252,"twenty":-15.620135,"median":-14.133223,"eighty":-13.26914,"marketCap":1537028403},{"date":"2026-09-18","current":-14.345155,"twenty":-15.433221,"median":-14.265483,"eighty":-13.287874,"marketCap":1482055365},{"date":"2026-09-25","current":-12.251097,"twenty":-15.425244,"median":-14.133223,"eighty":-13.26914,"marketCap":1265709862},{"date":"2026-09-29","current":-12.152402,"twenty":-15.410859,"median":-14.115811,"eighty":-13.252268,"marketCap":1255513250}],"updateTime":1790813335146},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AVLN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669162378","title":"Avalyn Pharma Reports Phase 1 Data for Inhaled Nintedanib AP02 Showing Higher Lung Exposure, Lower Systemic Levels","url":"https://stock-news.laohu8.com/highlight/detail?id=2669162378","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669162378?lang=en_us&edition=fundamental","pubTime":"2026-09-22 00:11","pubTimestamp":1790007085,"startTime":"0","endTime":"0","summary":"Avalyn Pharma reports Phase 1 data for inhaled nintedanib AP02 showing higher lung exposure, lower systemic levelsAvalyn Pharma flagged aRespiratory Researchpublication detailing Phase 1 trials of inh","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nNDLbxKbJx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BN0W2V16.EUR","BK4112","IE00BN0W2T93.GBP","IE00BQXX3C00.GBP","SG9999014005.SGD","IE00B64PRP62.GBP","BK4588","LU2095319765.USD","AVLN","SG9999014039.USD","SG9999014021.USD","LU2210150020.SGD","BCDF","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","BK4007","LU0314104364.USD","LU2210149790.SGD","IE00BN0W2W23.USD","SG9999014013.SGD","IE00BKPKM429.USD","NDAQ","IE00BQXX3F31.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669661341","title":"Avalyn Pharma announces published results from Phase 1 trials of AP02","url":"https://stock-news.laohu8.com/highlight/detail?id=2669661341","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669661341?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:10","pubTimestamp":1789996248,"startTime":"0","endTime":"0","summary":"Avalyn Pharma (AVLN) announced that Respiratory Research has published detailed results from two Phase 1 clinical trials of AP02 in healthy volunte...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-announces-published-results-from-phase-1-trials-of-ap02-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-announces-published-results-from-phase-1-trials-of-ap02-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED","AVLN","HYLG","IDNA","MEDX","NVIB","GDOC","BBC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668054994","title":"Avalyn Pharma Director Robert J. Meyer Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2668054994","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668054994?lang=en_us&edition=fundamental","pubTime":"2026-09-18 04:06","pubTimestamp":1789675617,"startTime":"0","endTime":"0","summary":"Avalyn Pharma Director Robert J. Meyer files initial beneficial ownership statementAvalyn Pharma director Robert J. Meyer filed an initial Form 3 beneficial ownership statement dated Sept. 15, 2026.Di","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nNDL9Q9vwJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVLN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668933628","title":"Avalyn Appoints Robert J. Meyer, Md, to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2668933628","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668933628?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:01","pubTimestamp":1789588860,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nTUA8THHQK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668933933","title":"Press Release: Avalyn Appoints Robert J. Meyer, MD, to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2668933933","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668933933?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:01","pubTimestamp":1789588860,"startTime":"0","endTime":"0","summary":"BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (\"Avalyn\" or the \"Company\"), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVLN","LABU","BK4007","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662620570","title":"Avalyn Pharma Advances Inhaled Pirfenidone AP01 in Phase 2b MIST Trial for Progressive Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2662620570","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662620570?lang=en_us&edition=fundamental","pubTime":"2026-08-25 04:01","pubTimestamp":1787601686,"startTime":"0","endTime":"0","summary":"Avalyn Pharma advances inhaled pirfenidone AP01 in Phase 2b MIST trial for progressive pulmonary fibrosisAvalyn Pharma slated two ERS Congress 2026 posters on Sept. 7 in Barcelona, spotlighting patien","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL2B5BVh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00B3QW5Z07.USD","NDAQ","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","LU0314104364.USD","SG9999014005.SGD","LU2210150020.SGD","LU2210149790.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","SG9999014039.USD","IE00BQXX3D17.EUR","AVLN","BK4585","BK4588","IE00B64PRP62.GBP","IE00BQXX3F31.USD","SG9999014021.USD","IE00BKPKM429.USD","BK4007","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BQXX3C00.GBP","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661298158","title":"One new option listing and two option delistings on August 21st","url":"https://stock-news.laohu8.com/highlight/detail?id=2661298158","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661298158?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:35","pubTimestamp":1787315738,"startTime":"0","endTime":"0","summary":"New option listings for August 21st include Avalyn Pharma Inc (AVLN). Option delistings effective August 21st include Liberty Broadband (LBRDK) and...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/one-new-option-listing-and-two-option-delistings-on-august-21st-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/one-new-option-listing-and-two-option-delistings-on-august-21st-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4100","BK4007","BK4561","LBRDK","BK4534","AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660424488","title":"Avalyn Pharma price target raised to $57 from $53 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2660424488","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660424488?lang=en_us&edition=fundamental","pubTime":"2026-08-17 16:02","pubTimestamp":1786953775,"startTime":"0","endTime":"0","summary":"Morgan Stanley raised the firm’s price target on Avalyn Pharma (AVLN) to $57 from $53 and keeps an Overweight rating on the shares. Published first...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-price-target-raised-to-57-from-53-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-price-target-raised-to-57-from-53-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659165881","title":"Jefferies Sticks to Its Buy Rating for Avalyn Pharma Inc (AVLN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659165881","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659165881?lang=en_us&edition=fundamental","pubTime":"2026-08-13 22:45","pubTimestamp":1786632342,"startTime":"0","endTime":"0","summary":"In a report released today, Roger Song from Jefferies maintained a Buy rating on Avalyn Pharma Inc, with a price target of $52.00. Song covers the ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-its-buy-rating-for-avalyn-pharma-inc-avln-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-its-buy-rating-for-avalyn-pharma-inc-avln-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659687091","title":"Avalyn Pharma is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2659687091","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659687091?lang=en_us&edition=fundamental","pubTime":"2026-08-13 22:26","pubTimestamp":1786631160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVLN/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658972423","title":"Avalyn Pharma Q2 EPS $(0.65) Misses $(0.53) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658972423","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658972423?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:13","pubTimestamp":1786536803,"startTime":"0","endTime":"0","summary":"Avalyn Pharma (NASDAQ:AVLN) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.53) by 22.64 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61138966/avalyn-pharma-q2-eps-0-65-misses-0-53-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658972464","title":"Earnings Flash (AVLN) Avalyn Pharma Posts Q2 Net Loss $28.9M, vs. FactSet Est of $28.6M Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2658972464","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658972464?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:12","pubTimestamp":1786536741,"startTime":"0","endTime":"0","summary":"Earnings Flash (AVLN) Avalyn Pharma Posts Q2 Net Loss $28.9M, vs. FactSet Est of $28.6M Loss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658115972","title":"Avalyn Pharma Q2 FY26 Net Loss Widens to $28.94 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658115972","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658115972?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:09","pubTimestamp":1786536565,"startTime":"0","endTime":"0","summary":"Avalyn Pharma Q2 FY26 net loss widens to $28.94 millionAvalyn Pharma posted a GAAP net loss of USD 28.9 million in Q2 2026, widening from USD 20.2 million a year earlier.R&D expense climbed to USD 24.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL1mnfcT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BN0W2V16.EUR","NDAQ","BCDF","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","IE00BKPKM429.USD","BK4007","BK4585","SG9999014021.USD","LU2095319765.USD","SG9999014013.SGD","AVLN","IE00BN0W2W23.USD","LU0314104364.USD","LU2210149790.SGD","BK4112","BK4588","IE00B3QW5Z07.USD","SG9999014005.SGD","SG9999014039.USD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658972189","title":"Press Release: Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2658972189","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658972189?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:00","pubTimestamp":1786536000,"startTime":"0","endTime":"0","summary":"double-blind, placebo-controlled global trial evaluating two doses of. AP01 dosed twice daily in patients with progressive pulmonary fibrosis. . This 52-week trial is designed to assess safety and efficacy of. AP01, with a primary endpoint of change in lung function measured by. forced vital capacity . The study overenrolled beyond its target. enrollment of 375, with a total of 398 patients randomized into three. treatment cohorts. Topline data are anticipated in the second half of. -- In September 2026, the Company plans to present two abstracts at the ERS. Congress in Barcelona, Spain. The first poster will highlight data. modeling effective AP01 distribution throughout the target tissue in both. healthy and idiopathic pulmonary fibrosis  lungs. The second poster. will describe the integration of patient perspectives into clinical trial. design. Detailed poster session information will be provided in advance","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","BK4007","MEDX","AVLN","NVIB","IDNA","FVC","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644450557","title":"Avalyn Pharma completes target enrollment in MIST trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2644450557","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644450557?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:15","pubTimestamp":1781698555,"startTime":"0","endTime":"0","summary":"Avalyn Pharma (AVLN) announced that it has completed target enrollment of 375 patients in the Phase 2b MIST clinical trial of AP01 in patients with...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-completes-target-enrollment-in-mist-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-completes-target-enrollment-in-mist-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MIST","AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644745938","title":"Avalyn Pharma completes enrollment in Phase 2b MIST trial of inhaled pirfenidone for progressive pulmonary fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2644745938","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644745938?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:02","pubTimestamp":1781697779,"startTime":"0","endTime":"0","summary":"Avalyn Pharma completed target enrollment of 375 patients in the Phase 2b MIST trial of AP01 for progressive pulmonary fibrosis.Results have not been presented; topline data are expected in the second half of 2027.The study is designed to assess whether inhaled pirfenidone can better preserve lung function versus placebo over 52 weeks.Management cited earlier-stage data suggesting tolerability that could support longer time on therapy, a potential differentiator in the disease.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL6CpYww:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014021.USD","LU2210149790.SGD","SG9999014013.SGD","LU0314104364.USD","BK4112","NDAQ","IE00BN0W2V16.EUR","BK4007","BK4588","SG9999014005.SGD","IE00BGHQF748.EUR","AVLN","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4585","IE00BN0W2W23.USD","IE00B64PRP62.GBP","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644745656","title":"Avalyn Pharma - Topline Data From Mist Trial Expected in Second Half of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2644745656","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644745656?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:00","pubTimestamp":1781697602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nTUA4X2JZZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVLN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644455937","title":"Avalyn Completes Target Enrollment in Phase 2B Mist Trial of AP01 (Inhaled Pirfenidone) for Patients With Progressive Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2644455937","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644455937?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:00","pubTimestamp":1781697602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nTUA4X2JZZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640906996","title":"Avalyn Pharma FY26 Q1 net loss widens to $26.87 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2640906996","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640906996?lang=en_us&edition=fundamental","pubTime":"2026-06-03 19:02","pubTimestamp":1780484537,"startTime":"0","endTime":"0","summary":"Avalyn Pharma posted a net loss of $26.87 million, widening from $17.5 million a year earlier.R&D expenses climbed to $22.89 million from $15.32 million, while G&A costs rose to $5.02 million from $3.4 million.Cash, cash equivalents, and marketable securities fell to $123.13 million as of March 31, excluding $316.1 million in IPO net proceeds.The upsized IPO raised $345 million in gross proceeds; cash including IPO proceeds is expected to fund operations into 2029.AP01 MIST Phase 2b enrollment is targeted to finish mid-2026 with topline data in 2H 2027; AP02 AURA Phase 2 topline data are expected in late 2027.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL1Fl8bB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4588","LU2210149790.SGD","IE00BN0W2T93.GBP","BK4007","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK4585","LU2210150020.SGD","AVLN","IE00BKPKM429.USD","SG9999014005.SGD","SG9999014021.USD","IE00BN0W2W23.USD","SG9999014039.USD","IE00B64PRP62.GBP","NDAQ","LU2095319765.USD","IE00BGHQF748.EUR","BK4112","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640906579","title":"Press Release: Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2640906579","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640906579?lang=en_us&edition=fundamental","pubTime":"2026-06-03 19:00","pubTimestamp":1780484400,"startTime":"0","endTime":"0","summary":"On track to complete enrollment of MIST Phase 2b trial of AP01 in progressive pulmonary fibrosis  in mid-2026, with newly presented long term open-label extension clinical data that support favorable tolerability profile. Enrollment underway in AURA Phase 2 trial of AP02 in patients with idiopathic pulmonary fibrosis  with topline data anticipated by the end of 2027. Upsized initial public offering  gross proceeds of $345.0 million, together with approximately $123.1 million in cash, cash equivalents, and marketable securities as of March 31, 2026, projected to be sufficient to fund operations into 2029. BOSTON, June 03, 2026  -- Avalyn Pharma Inc. , a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced financial results for the first quarter ended March 31, 2026 and recent business highlights.-- MIST Phase 2b Trial On-Track to Complete Enrollment Mid-2026, with. placebo-control","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATS","R","BK4007","BK4232","AVLN","BK4022","BK4161","IPO"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":51,"code":"91000000","status":"200"}]}}